Co-occurring genomic alterations in non-small-cell lung cancer

The improbable targeted therapy: KRAS as an emerging target in non

PDF) Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

A Look at NSCLC and Its Current and Emerging Therapies

IJMS, Free Full-Text

Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. - Abstract - Europe PMC

PDF) Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

Full article: Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics

Cancers, Free Full-Text

Biomedicines, Free Full-Text

PDF] Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement - Modern Pathology

Cancer genome and tumor microenvironment: Reciprocal crosstalk